Skip to Content

Psoriatic Arthritis Patients Achieving Robust Treatment Targets Experience Better Outcomes

The PsABio study sought to evaluate the real-world effectiveness and safety of ustekinumab (UST) and tumor necrosis factor inhibitors (TNFi) over three years in treating psoriatic arthritis (PsA).

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top